Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006028248> ?p ?o ?g. }
- W3006028248 endingPage "1224" @default.
- W3006028248 startingPage "1214" @default.
- W3006028248 abstract "Background: In patients with transthyretin amyloid cardiomyopathy, tafamidis reduces all-cause mortality and cardiovascular hospitalizations and slows decline in quality of life compared with placebo. In May 2019, tafamidis received expedited approval from the US Food and Drug Administration as a breakthrough drug for a rare disease. However, at $225 000 per year, it is the most expensive cardiovascular drug ever launched in the United States, and its long-term cost-effectiveness and budget impact are uncertain. We therefore aimed to estimate the cost-effectiveness of tafamidis and its potential effect on US health care spending. Methods: We developed a Markov model of patients with wild-type or variant transthyretin amyloid cardiomyopathy and heart failure (mean age, 74.5 years) using inputs from the ATTR-ACT trial (Transthyretin Amyloidosis Cardiomyopathy Clinical Trial), published literature, US Food and Drug Administration review documents, healthcare claims, and national survey data. We compared no disease–specific treatment (“usual care”) with tafamidis therapy. The model reproduced 30-month survival, quality of life, and cardiovascular hospitalization rates observed in ATTR-ACT; future projections used a parametric survival model in the control arm, with constant hazards reduction in the tafamidis arm. We discounted future costs and quality-adjusted life-years by 3% annually and examined key parameter uncertainty using deterministic and probabilistic sensitivity analyses. The main outcomes were lifetime incremental cost-effectiveness ratio and annual budget impact, assessed from the US healthcare sector perspective. This study was independent of the ATTR-ACT trial sponsor. Results: Compared with usual care, tafamidis was projected to add 1.29 (95% uncertainty interval, 0.47–1.75) quality-adjusted life-years at an incremental cost of $1 135 000 (872 000–1 377 000), resulting in an incremental cost-effectiveness ratio of $880 000 (697 000–1 564 000) per quality-adjusted life-year gained. Assuming a threshold of $100 000 per quality-adjusted life-year gained and current drug price, tafamidis was cost-effective in 0% of 10 000 probabilistic simulations. A 92.6% price reduction from $225 000 to $16 563 would be necessary to make tafamidis cost-effective at $100 000/quality-adjusted life-year. Results were sensitive to assumptions related to long-term effectiveness of tafamidis. Treating all eligible patients with transthyretin amyloid cardiomyopathy in the United States with tafamidis (n=120 000) was estimated to increase annual healthcare spending by $32.3 billion. Conclusions: Treatment with tafamidis is projected to produce substantial clinical benefit but would greatly exceed conventional cost-effectiveness thresholds at the current US list price. On the basis of recent US experience with high-cost cardiovascular medications, access to and uptake of this effective therapy may be limited unless there is a large reduction in drug costs." @default.
- W3006028248 created "2020-02-24" @default.
- W3006028248 creator A5005215114 @default.
- W3006028248 creator A5015021993 @default.
- W3006028248 creator A5016472411 @default.
- W3006028248 creator A5024220356 @default.
- W3006028248 creator A5027510418 @default.
- W3006028248 creator A5036864965 @default.
- W3006028248 creator A5045032519 @default.
- W3006028248 creator A5056258305 @default.
- W3006028248 creator A5059417970 @default.
- W3006028248 creator A5063081757 @default.
- W3006028248 creator A5089120659 @default.
- W3006028248 date "2020-04-14" @default.
- W3006028248 modified "2023-10-13" @default.
- W3006028248 title "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy" @default.
- W3006028248 cites W1238951602 @default.
- W3006028248 cites W1995945562 @default.
- W3006028248 cites W2044591445 @default.
- W3006028248 cites W2062245141 @default.
- W3006028248 cites W2072727975 @default.
- W3006028248 cites W2083650930 @default.
- W3006028248 cites W2511907480 @default.
- W3006028248 cites W2517239280 @default.
- W3006028248 cites W2519603001 @default.
- W3006028248 cites W2756030371 @default.
- W3006028248 cites W2759629908 @default.
- W3006028248 cites W2888036721 @default.
- W3006028248 cites W2905951279 @default.
- W3006028248 cites W2948364217 @default.
- W3006028248 cites W2952648944 @default.
- W3006028248 cites W2961150583 @default.
- W3006028248 cites W4237383128 @default.
- W3006028248 doi "https://doi.org/10.1161/circulationaha.119.045093" @default.
- W3006028248 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7156331" @default.
- W3006028248 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32078382" @default.
- W3006028248 hasPublicationYear "2020" @default.
- W3006028248 type Work @default.
- W3006028248 sameAs 3006028248 @default.
- W3006028248 citedByCount "127" @default.
- W3006028248 countsByYear W30060282482020 @default.
- W3006028248 countsByYear W30060282482021 @default.
- W3006028248 countsByYear W30060282482022 @default.
- W3006028248 countsByYear W30060282482023 @default.
- W3006028248 crossrefType "journal-article" @default.
- W3006028248 hasAuthorship W3006028248A5005215114 @default.
- W3006028248 hasAuthorship W3006028248A5015021993 @default.
- W3006028248 hasAuthorship W3006028248A5016472411 @default.
- W3006028248 hasAuthorship W3006028248A5024220356 @default.
- W3006028248 hasAuthorship W3006028248A5027510418 @default.
- W3006028248 hasAuthorship W3006028248A5036864965 @default.
- W3006028248 hasAuthorship W3006028248A5045032519 @default.
- W3006028248 hasAuthorship W3006028248A5056258305 @default.
- W3006028248 hasAuthorship W3006028248A5059417970 @default.
- W3006028248 hasAuthorship W3006028248A5063081757 @default.
- W3006028248 hasAuthorship W3006028248A5089120659 @default.
- W3006028248 hasBestOaLocation W30060282481 @default.
- W3006028248 hasConcept C121157162 @default.
- W3006028248 hasConcept C126322002 @default.
- W3006028248 hasConcept C159110408 @default.
- W3006028248 hasConcept C160735492 @default.
- W3006028248 hasConcept C162324750 @default.
- W3006028248 hasConcept C177713679 @default.
- W3006028248 hasConcept C2778198053 @default.
- W3006028248 hasConcept C2778797674 @default.
- W3006028248 hasConcept C2779951463 @default.
- W3006028248 hasConcept C50522688 @default.
- W3006028248 hasConcept C535046627 @default.
- W3006028248 hasConcept C71924100 @default.
- W3006028248 hasConceptScore W3006028248C121157162 @default.
- W3006028248 hasConceptScore W3006028248C126322002 @default.
- W3006028248 hasConceptScore W3006028248C159110408 @default.
- W3006028248 hasConceptScore W3006028248C160735492 @default.
- W3006028248 hasConceptScore W3006028248C162324750 @default.
- W3006028248 hasConceptScore W3006028248C177713679 @default.
- W3006028248 hasConceptScore W3006028248C2778198053 @default.
- W3006028248 hasConceptScore W3006028248C2778797674 @default.
- W3006028248 hasConceptScore W3006028248C2779951463 @default.
- W3006028248 hasConceptScore W3006028248C50522688 @default.
- W3006028248 hasConceptScore W3006028248C535046627 @default.
- W3006028248 hasConceptScore W3006028248C71924100 @default.
- W3006028248 hasIssue "15" @default.
- W3006028248 hasLocation W30060282481 @default.
- W3006028248 hasLocation W30060282482 @default.
- W3006028248 hasOpenAccess W3006028248 @default.
- W3006028248 hasPrimaryLocation W30060282481 @default.
- W3006028248 hasRelatedWork W1617225148 @default.
- W3006028248 hasRelatedWork W2002495768 @default.
- W3006028248 hasRelatedWork W2031642818 @default.
- W3006028248 hasRelatedWork W2088617309 @default.
- W3006028248 hasRelatedWork W2115795314 @default.
- W3006028248 hasRelatedWork W2166041505 @default.
- W3006028248 hasRelatedWork W2948855589 @default.
- W3006028248 hasRelatedWork W2968096731 @default.
- W3006028248 hasRelatedWork W4210750243 @default.
- W3006028248 hasRelatedWork W4247718175 @default.
- W3006028248 hasVolume "141" @default.
- W3006028248 isParatext "false" @default.